Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BHVN Biohaven	$23.67 +4.7%	$34.21	$21.47 ▼ $55.72	$2.31B	1.33	1.08 million shs	1.12 million shs
MLTX MoonLake Immunotherapeutics	$38.05 +4.7%	$41.71	$35.39 ▼ $58.26	$2.44B	1.31	340,569 shs	680,471 shs
RARE Ultragenyx Pharmaceutical	$35.37 +4.5%	$41.26	$33.53 ▼ $60.37	$3.32B	0.61	789,917 shs	570,886 shs
RYZB RayzeBio	$62.49	$62.47	$17.95 ▼ $62.51	$3.74B	N/A	553,592 shs	N/A

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BHVN Biohaven	+4.76%	-17.94%	-25.87%	-36.51%	-53.36%
MLTX MoonLake Immunotherapeutics	+4.68%	-0.89%	-4.18%	-28.97%	-19.47%
RARE Ultragenyx Pharmaceutical	+4.52%	-6.87%	-14.28%	-14.05%	-24.08%
RYZB RayzeBio	0.00%	0.00%	0.00%	0.00%	0.00%

Remove Ads

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BHVN Biohaven	3.9799 of 5 stars	4.5	3.0	0.0	0.0	2.5	4.2	0.6
MLTX MoonLake Immunotherapeutics	1.9816 of 5 stars	3.5	1.0	0.0	0.0	2.7	2.5	0.0
RARE Ultragenyx Pharmaceutical	4.4343 of 5 stars	4.5	1.0	0.0	3.8	3.3	2.5	0.6
RYZB RayzeBio	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BHVN Biohaven	3.07	Buy	$62.77	165.18% Upside
MLTX MoonLake Immunotherapeutics	3.00	Buy	$80.50	111.56% Upside
RARE Ultragenyx Pharmaceutical	2.93	Moderate Buy	$92.79	162.33% Upside
RYZB RayzeBio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest RYZB, RARE, BHVN, and MLTX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
3/27/2025	RARE Ultragenyx Pharmaceutical	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$104.00 ➝ $117.00
3/20/2025	BHVN Biohaven	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$60.00
3/18/2025	MLTX MoonLake Immunotherapeutics	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$67.00
3/17/2025	RARE Ultragenyx Pharmaceutical	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$140.00 ➝ $115.00
3/7/2025	BHVN Biohaven	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$69.00 ➝ $63.00
3/5/2025	BHVN Biohaven	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$72.00 ➝ $68.00
3/4/2025	BHVN Biohaven	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$54.00 ➝ $54.00
3/4/2025	BHVN Biohaven	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$61.00 ➝ $61.00
2/27/2025	MLTX MoonLake Immunotherapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$82.00 ➝ $73.00
2/27/2025	MLTX MoonLake Immunotherapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$62.00 ➝ $66.00
2/27/2025	MLTX MoonLake Immunotherapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$100.00 ➝ $100.00

(Data available from 4/3/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BHVN Biohaven	N/A	N/A	N/A	N/A	$5.34 per share	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	$8.15 per share	N/A
RARE Ultragenyx Pharmaceutical	$560.23M	5.93	N/A	N/A	$2.76 per share	12.82
RYZB RayzeBio	N/A	N/A	N/A	N/A	N/A	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BHVN Biohaven	-$408.17M	-$9.39	N/A	N/A	N/A	N/A	-225.12%	-158.89%	5/8/2025 (Estimated)
MLTX MoonLake Immunotherapeutics	-$36.01M	-$1.89	N/A	N/A	N/A	N/A	-15.54%	-15.09%	5/6/2025 (Estimated)
RARE Ultragenyx Pharmaceutical	-$569.18M	-$6.34	N/A	N/A	N/A	-101.60%	-193.80%	-38.15%	5/1/2025 (Estimated)
RYZB RayzeBio	-$68.60M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest RYZB, RARE, BHVN, and MLTX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/1/2025	N/A	RARE Ultragenyx Pharmaceutical	-$1.58	N/A	N/A	N/A	$145.98 million	N/A
3/3/2025	Q4 2024	BHVN Biohaven	-$1.56	-$1.85	-$0.29	-$1.85	$100.00 million	N/A
2/26/2025	Q4 2024	MLTX MoonLake Immunotherapeutics	-$0.63	-$0.72	-$0.09	-$0.72	N/A	N/A
2/13/2025	Q4 2024	RARE Ultragenyx Pharmaceutical	-$1.32	-$1.39	-$0.07	-$1.39	$163.23 million	$164.88 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BHVN Biohaven	N/A	N/A	N/A	N/A	N/A
MLTX MoonLake Immunotherapeutics	N/A	N/A	N/A	N/A	N/A
RARE Ultragenyx Pharmaceutical	N/A	N/A	N/A	N/A	N/A
RYZB RayzeBio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BHVN Biohaven	N/A	2.89	2.89
MLTX MoonLake Immunotherapeutics	N/A	25.51	25.51
RARE Ultragenyx Pharmaceutical	N/A	2.37	2.65
RYZB RayzeBio	N/A	31.85	31.85

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BHVN Biohaven	88.78%
MLTX MoonLake Immunotherapeutics	93.85%
RARE Ultragenyx Pharmaceutical	97.67%
RYZB RayzeBio	N/A

Insider Ownership

Company	Insider Ownership
BHVN Biohaven	16.00%
MLTX MoonLake Immunotherapeutics	12.02%
RARE Ultragenyx Pharmaceutical	5.80%
RYZB RayzeBio	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BHVN Biohaven	239	102.07 million	84.94 million	Optionable
MLTX MoonLake Immunotherapeutics	2	64.01 million	56.22 million	Optionable
RARE Ultragenyx Pharmaceutical	1,310	93.89 million	86.99 million	Optionable
RYZB RayzeBio	88	59.92 million	N/A	Optionable

RYZB, RARE, BHVN, and MLTX Headlines

Recent News About These Companies

Double IPOs headline this week's biotech financings

March 23, 2025 | pharmaphorum.com

Esports Entertainment (OTC:GMBL) Stock Quotes, Forecast and News Summary

October 4, 2024 | benzinga.com

NextPlay Technologies (OTC:NXTP) Stock Quotes, Forecast and News Summary

October 4, 2024 | benzinga.com

LeddarTech Holdings (NASDAQ:LDTC) Stock Quotes, Forecast and News Summary

October 3, 2024 | benzinga.com

BMS strikes again, with $4.1bn RayzeBio takeover bid

August 2, 2024 | pharmaphorum.com

Getting In on This "Macro-Trend"

May 10, 2024 | nasdaq.com

Andreas Halvorsen's Firm Sells Out of RayzeBio Inc

February 29, 2024 | finance.yahoo.com

RYZB Aug 2024 35.000 put

February 27, 2024 | finance.yahoo.com

RYZB May 2024 55.000 put

February 27, 2024 | finance.yahoo.com

Bristol Myers Squibb Completes Acquisition of RayzeBio, Adding Differentiated Actinium-Based Radiopharmaceutical Platform

February 26, 2024 | businesswire.com

BMY Mar 2024 54.000 put

February 25, 2024 | ca.finance.yahoo.com

BMY Apr 2024 43.000 put

February 24, 2024 | finance.yahoo.com

BMY Mar 2024 48.000 call

February 24, 2024 | finance.yahoo.com

BMY Mar 2024 47.000 put

February 24, 2024 | finance.yahoo.com

BMY Mar 2024 43.000 put

February 24, 2024 | finance.yahoo.com

Bristol Myers Wraps RayzeBio Tender Offer with 86% of Shares

February 23, 2024 | marketwatch.com

Bristol Myers Squibb Announces Expiration of RayzeBio Tender Offer

February 23, 2024 | businesswire.com

RayzeBio Stock (NASDAQ:RYZB), Quotes and News Summary

February 22, 2024 | benzinga.com

RYZB Feb 2024 65.000 call

February 18, 2024 | finance.yahoo.com

BMY Feb 2024 37.000 put

February 13, 2024 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Warren Buffett Swaps VOO for This Reliable Dividend Stock
By Sarah Horvath | March 7, 2025
View Warren Buffett Swaps VOO for This Reliable Dividend Stock
NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
By Thomas Hughes | March 12, 2025
View NVIDIA’s Soaring Energy Needs Make These 3 Nuclear Stocks a Buy
BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
By Jeffrey Neal Johnson | March 21, 2025
View BYD Unveils Ultra-Fast Charging—Will It Supercharge BYDDY Stock?
Everything About Amazon Stock Signals a Buy—Time to Load Up?
By Sam Quirke | March 20, 2025
View Everything About Amazon Stock Signals a Buy—Time to Load Up?
Samsara Stock Plunges, But Technicals Flash a Buy Signal
By Sam Quirke | March 12, 2025
View Samsara Stock Plunges, But Technicals Flash a Buy Signal

RYZB, RARE, BHVN, and MLTX Company Descriptions

Biohaven NYSE:BHVN

$23.67 +1.07 (+4.73%)

Closing price 04/2/2025 03:59 PM Eastern

Extended Trading

$22.62 -1.05 (-4.41%)

As of 04:01 AM Eastern

Biohaven Ltd., together with its subsidiaries, focuses on discovering, developing, and commercializing therapies for immunology, neuroscience, and oncology worldwide. The company's pipeline products include Troriluzole, which is in Phase 3 clinical trial for the treatment of neurological and neuropsychiatric illnesses; BHV-5500 that blocks glutamate signaling mediated by post-synaptic NMDA receptors; Taldefgrobep Alfa, which is in Phase 3 clinical trial for the treatment of spinal muscular atrophy and obesity; BHV-7000, a candidate in Phase 2/3 clinical trials for the treatment of focal and generalized epilepsy, bipolar disorder, and major depressive disorder; BHV-2100 that is in Phase 1 clinical trials for the treatment of migraines and neuropathic pain; and BHV-8000, a product candidate in Phase 1 clinical trials for the treatment of early Alzheimer's and Parkinson's disease, sclerosis, and amyloid-related imaging abnormalities. It also offers BHV-1300, a product candidate in Phase 1 clinical trials to treat rheumatoid arthritis; BHV-1310 for the treatment of generalized myasthenia gravis and acute exacerbations or flares; BHV-1400 to treat IgA Nephropathy; and BHV-1600 for the treatment of dilated cardiomyopathy. In addition, the company develops BHV-1100, a product candidate in Phase 1a/1b clinical trials for multiple myeloma patients; BHV-1510, a preclinical product that targets carcinomas; and BHV-1500 for Hodgkin's lymphoma. It has license, development, and commercialization agreements with Yale University, AstraZeneca, University of Connecticut, Artizan Biosciences Inc., Reliant Glycosciences LLC, Katholieke Universiteit Leuven, BMS, and Highlightll Pharmaceutical Co. Ltd. The company was formerly known as Biohaven Research Ltd and changed its name to Biohaven Ltd. in September 2022. Biohaven Ltd. was incorporated in 2022 and is headquartered in New Haven, Connecticut.

MoonLake Immunotherapeutics NASDAQ:MLTX

$38.05 +1.70 (+4.68%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$37.12 -0.92 (-2.43%)

As of 04:39 AM Eastern

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.

Ultragenyx Pharmaceutical NASDAQ:RARE

$35.37 +1.53 (+4.52%)

Closing price 04/2/2025 04:00 PM Eastern

Extended Trading

$37.01 +1.64 (+4.62%)

As of 04:21 AM Eastern

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.

RayzeBio NASDAQ:RYZB

RayzeBio, Inc. develops radiopharmaceutical therapeutics (RPT) for the treatment of cancer. The company's lead drug candidate is RYZ101, which is in phase 3 clinical trial for the treatment of gasteroenteropancreatic neuroendocrine tumors (GEP-NETs). It also develops RYZ801, a novel proprietary peptide that targets GPC3 for delivery of Ac225 for the treatment of hepatocellular carcinoma (HCC); RYZ811, a paired diagnostic imaging agent with the peptide binder, chelator, and Ga68 as the radioisotope; and a novel proprietary small molecule that targets CA9 for delivery of Ac225 for the treatment of ccRCC. The company was incorporated in 2020 and is based in San Diego, California. As of February 26, 2024, RayzeBio, Inc. operates as a subsidiary of Bristol-Myers Squibb Company.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time